OTC · ELOX
Healthcare · Biotechnology
$15.13
Down-$0.28 (-1.82%)
Updated Oct 7, 2026, 3:57 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ELOX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
ELOX closed at $15.13 after 21 trading sessions, down 6.43% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $15.34 | $16.02 | $14.50 | $15.13 | 61.29K |
| Oct 5, 2026 | $15.25 | $16.81 | $15.25 | $15.41 | 26.16K |
| Oct 2, 2026 | $15.92 | $16.0173 | $14.91 | $15.51 | 17.71K |
| Oct 1, 2026 | $15.22 | $16.295 | $15.22 | $15.71 | 10.87K |
| Sep 30, 2026 | $14.94 | $15.71 | $14.4201 | $15.31 | 14.33K |
| Sep 29, 2026 | $15.4062 | $15.45 | $14.787 | $15.42 | 6.08K |
| Sep 28, 2026 | $15.69 | $15.69 | $14.3518 | $15.00 | 16.41K |
| Sep 25, 2026 | $15.95 | $16.36 | $14.04 | $15.03 | 27.61K |
| Sep 24, 2026 | $16.65 | $16.71 | $15.6021 | $16.00 | 28.9K |
| Sep 23, 2026 | $16.56 | $16.56 | $14.50 | $15.435 | 20.26K |
| Sep 22, 2026 | $17.01 | $17.5824 | $16.43 | $16.73 | 15.82K |
| Sep 21, 2026 | $17.36 | $18.2493 | $17.06 | $17.19 | 22.35K |
| Sep 18, 2026 | $18.98 | $18.98 | $17.24 | $17.45 | 66.53K |
| Sep 17, 2026 | $17.75 | $18.50 | $17.41 | $17.55 | 12.41K |
| Sep 16, 2026 | $18.24 | $18.95 | $17.57 | $17.63 | 18K |
| Sep 15, 2026 | $16.23 | $18.97 | $16.17 | $18.25 | 40.69K |
| Sep 14, 2026 | $15.40 | $16.30 | $15.00 | $16.30 | 16.53K |
| Sep 11, 2026 | $16.74 | $17.19 | $15.00 | $15.75 | 17.17K |
| Sep 10, 2026 | $16.50 | $17.15 | $15.745 | $16.28 | 28.69K |
| Sep 9, 2026 | $16.03 | $17.74 | $15.16 | $16.57 | 37.44K |
| Sep 8, 2026 | $15.49 | $17.42 | $15.0001 | $16.17 | 29.18K |
The latest Smart Investors Daily articles mentioning ELOX.
Company
Market Activity
Research & News
ELOX research
Company profile and research snapshot.
ELOXX PHARMACEUTICALS INC
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | Leerink Partners | Outperform | — |
| Aug 24, 2026 | Guggenheim | Buy | — |
| Aug 20, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Jul 22, 2026 | LifeSci Capital | Outperform | — |
| Jul 20, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 28, 2026
Gainers Kodiak Sciences (NASDAQ:KOD) shares increased by 57.4% to $50.93 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) stock moved
Benzinga · Sep 18, 2026
Leerink Partners analyst Joseph Schwartz initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $32.
Yahoo · Sep 11, 2026
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that the first two patients have been dosed in the EXACT Study, a Phase 2b clinical trial evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS).
Benzinga · Aug 24, 2026
Guggenheim analyst Vamil Divan reiterates Eloxx Pharma (NASDAQ:ELOX) with a Buy and maintains $43 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ELOX.
